Top

Published in:

01-04-2012 | PRECLINICAL STUDIES

Vandetanib mediates anti-leukemia activity by multiple mechanisms and interacts synergistically with DNA damaging agents

Authors: Margaret E. Macy, Deborah DeRyckere, Lia Gore

Published in: Investigational New Drugs | Issue 2/2012

Summary

Vandetanib is an orally active small molecule tyrosine kinase inhibitor (TKI) with activity against several pathways implicated in malignancy including the vascular endothelial growth factor receptor pathway, the epidermal growth factor receptor pathway, the platelet derived growth factor receptor β pathway, and REarranged during Transfection pathway. To determine if vandetanib-mediated inhibition of receptor tyrosine kinases is a potential therapeutic strategy for pediatric acute leukemia, these studies aimed to characterize the activity of vandetanib against acute leukemia in vitro. Treatment of leukemia cell lines with vandetanib resulted in a dose-dependent decrease in proliferation and survival. Vandetanib’s anti-leukemic activity appeared mediated by multiple mechanisms including accumulation in G1 phase at lower concentrations and apoptosis at higher concentrations. Alterations in cell surface markers also occurred with vandetanib treatment, suggesting induction of differentiation. In combination with DNA damaging agents (etoposide and doxorubicin) vandetanib demonstrated synergistic induction of cell death. However in combination with the anti-metabolite methotrexate, vandetanib had an antagonistic effect on cell death. Although several targets of vandetanib are expressed on acute leukemia cell lines, expression of vandetanib targets did not predict vandetanib sensitivity and alone are therefore not likely candidate biomarkers in patients with acute leukemia. Interactions between vandetanib and standard chemotherapy agents in vitro may help guide choice of combination regimens for further evaluation in the clinical setting for patients with relapsed/refractory acute leukemia. Taken together, these preclinical data support clinical evaluation of vandetanib, in combination with cytotoxic chemotherapy, for pediatric leukemia.

Available only for authorised users

Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, Altekruse SF, Feuer EJ, Huang L, Mariotto A, Miller BA, Lewis DR, Eisner MP, Stinchcomb DG, Be E (2009) Seer cancer statistics review, 1975–2006. National Cancer Institute, Bethesda

Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics, 2006. CA Cancer J Clin 56(2):106–130PubMedCrossRef

Chessells JM (1998) Relapsed lymphoblastic leukaemia in children: a continuing challenge. Br J Haematol 102(2):423–438PubMedCrossRef

Behm FG, Raimondi SC, Frestedt JL, Liu Q, Crist WM, Downing JR, Rivera GK, Kersey JH, Pui CH (1996) Rearrangement of the mll gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age. Blood 87(7):2870–2877PubMed

Kang H, Chen IM, Wilson CS, Bedrick EJ, Harvey RC, Atlas SR, Devidas M, Mullighan CG, Wang X, Murphy M, Ar K, Wharton W, Borowitz MJ, Bowman WP, Bhojwani D, Carroll WL, Camitta BM, Reaman GH, Smith MA, Downing JR, Hunger SP, Willman CL (2010) Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric b-precursor acute lymphoblastic leukemia. Blood 115(7):1394–1405. doi:10.1182/blood-2009-05-218560 PubMedCrossRef

Pui CH, Gaynon PS, Boyett JM, Chessells JM, Baruchel A, Kamps W, Silverman LB, Biondi A, Harms DO, Vilmer E, Schrappe M, Camitta B (2002) Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 359(9321):1909–1915. doi:10.1016/S0140-6736(02)08782-2 PubMedCrossRef

Gaynon PS, Harris RE, Altman AJ, Bostrom BC, Breneman JC, Hawks R, Steele D, Zipf T, Stram DO, Villaluna D, Trigg ME (2006) Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: children’s oncology group study ccg-1941. J Clin Oncol 24(19):3150–3156. doi:10.1200/JCO.2005.04.5856 PubMedCrossRef

Rivera GK, Zhou Y, Hancock ML, Gajjar A, Rubnitz J, Ribeiro RC, Sandlund JT, Hudson M, Relling M, Evans WE, Pui CH (2005) Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia. Cancer 103(2):368–376. doi:10.1002/cncr.20743 PubMedCrossRef

Ko RH, Ji L, Barnette P, Bostrom B, Hutchinson R, Raetz E, Seibel NL, Twist CJ, Eckroth E, Sposto R, Gaynon PS, Loh ML (2010) Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia consortium study. J Clin Oncol 28(4):648–654. doi:10.1200/JCO.2009.22.2950 PubMedCrossRef

10.

Ferrara N, Gerber HP, LeCouter J (2003) The biology of vegf and its receptors. Nat Med 9(6):669–676PubMedCrossRef

11.

Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23(5):1011–1027. doi:10.1200/jco.2005.06.081 PubMedCrossRef

12.

Zhan P, Wang J, Lv XJ, Wang Q, Qiu LX, Lin XQ, Yu LK, Song Y (2009) Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J Thorac Oncol 4(9):1094–1103. doi:10.1097/JTO.0b013e3181a97e31 PubMedCrossRef

13.

Linderholm B, Tavelin B, Grankvist K, Henriksson R (1998) Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J Clin Oncol 16(9):3121–3128PubMed

14.

Lee JC, Chow NH, Wang ST, Huang SM (2000) Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 36(6):748–753PubMedCrossRef

15.

Li L, Wang L, Zhang W, Tang B, Zhang J, Song H, Yao D, Tang Y, Chen X, Yang Z, Wang G, Li X, Zhao J, Ding H, Reed E, Li QQ (2004) Correlation of serum vegf levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer. Anticancer Res 24(3b):1973–1979PubMed

16.

Hennequin LF, Stokes ES, Thomas AP, Johnstone C, Ple PA, Ogilvie DJ, Dukes M, Wedge SR, Kendrew J, Curwen JO (2002) Novel 4-anilinoquinazolines with c-7 basic side chains: design and structure activity relationship of a series of potent, orally active, vegf receptor tyrosine kinase inhibitors. J Med Chem 45(6):1300–1312PubMedCrossRef

17.

Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Ryan AJ, Fontanini G, Fusco A, Santoro M (2002) Zd6474, an orally available inhibitor of kdr tyrosine kinase activity, efficiently blocks oncogenic ret kinases. Cancer Res 62(24):7284–7290PubMed

18.

Ciardiello F, Caputo R, Damiano V, Caputo R, Troiani T, Vitagliano D, Carlomagno F, Veneziani BM, Fontanini G, Bianco AR, Tortora G (2003) Antitumor effects of zd6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 9(4):1546–1556PubMed

19.

Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA, Hughes GD, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF, Bigley AL, Hennequin LF (2002) Zd6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62(16):4645–4655PubMed

20.

Holden SN, Eckhardt SG, Basser R, de Boer R, Rischin D, Green M, Rosenthal MA, Wheeler C, Barge A, Hurwitz HI (2005) Clinical evaluation of zd6474, an orally active inhibitor of vegf and egf receptor signaling, in patients with solid, malignant tumors. Ann Oncol 16(8):1391–1397PubMedCrossRef

21.

Tamura T, Minami H, Yamada Y, Yamamoto N, Shimoyama T, Murakami H, Horiike A, Fujisaka Y, Shinkai T, Tahara M, Kawada K, Ebi H, Sasaki Y, Jiang H, Saijo N (2006) A phase i dose-escalation study of zd6474 in japanese patients with solid, malignant tumors. J Thorac Oncol 1(9):1002–1009PubMedCrossRef

22.

Natale RB, Bodkin D, Govindan R, Sleckman BG, Rizvi NA, Capo A, Germonpre P, Eberhardt WE, Stockman PK, Kennedy SJ, Ranson M (2009) Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study. J Clin Oncol 27(15):2523–2529. doi:10.1200/JCO.2008.18.6015 PubMedCrossRef

23.

Heymach JV, Paz-Ares L, De Braud F, Sebastian M, Stewart DJ, Eberhardt WE, Ranade AA, Cohen G, Trigo JM, Sandler AB, Bonomi PD, Herbst RS, Krebs AD, Vasselli J, Johnson BE (2008) Randomized phase ii study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 26(33):5407–5415. doi:10.1200/JCO.2008.17.3138 PubMedCrossRef

24.

Johnson BE, Ma P, West H, Kerr R, Prager D, Sandler A, Herbst RS, Stewart DJ, Dimery IW, Heymach JV (2005) Preliminary phase ii safety evaluation of zd6474, in combination with carboplatin and paclitaxel, as 1st-line treatment in patients with nsclc. J Clin Oncol (Meeting Abstracts) 23(16_suppl):7102

25.

Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J, Schlumberger M (2010) Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 28(5):767–772. doi:10.1200/JCO.2009.23.6604 PubMedCrossRef

26.

Miller KD, Trigo JM, Wheeler C, Barge A, Rowbottom J, Sledge G, Baselga J (2005) A multicenter phase ii trial of zd6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res 11(9):3369–3376. doi:10.1158/1078-0432.CCR-04-1923 PubMedCrossRef

27.

Nallapareddy S, Eckhardt S, O’Bryant C, Eppers S, Diab S, Kane M, Weekes C, Spratlin J, Messersmith W, Leong S (2010) A phase i study of gemcitabine, capecitabine and vandetanib in patients with advanced solid tumors with an expanded cohort in biliary and pancreatic malignancies. Paper presented at the American Society of Clinical Oncology, Chicago, IL

28.

Carlomagno F, Santoro M (2004) Identification of ret kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer. J Chemother 16(Suppl 4):49–51PubMed

29.

Vidal M, Wells S, Ryan A, Cagan R (2005) Zd6474 suppresses oncogenic ret isoforms in a drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma. Cancer Res 65(9):3538–3541. doi:10.1158/0008-5472.CAN-04-4561 PubMedCrossRef

30.

Fragoso R, Elias AP, Dias S (2007) Autocrine vegf loops, signaling pathways, and acute leukemia regulation. Leuk Lymphoma 48(3):481–488PubMedCrossRef

31.

Santos SC, Dias S (2004) Internal and external autocrine vegf/kdr loops regulate survival of subsets of acute leukemia through distinct signaling pathways. Blood 103(10):3883–3889PubMedCrossRef

32.

Avramis IA, Panosyan EH, Dorey F, Holcenberg JS, Avramis VI (2006) Correlation between high vascular endothelial growth factor-a serum levels and treatment outcome in patients with standard-risk acute lymphoblastic leukemia: A report from children’s oncology group study ccg-1962. Clin Cancer Res 12(23):6978–6984PubMedCrossRef

33.

Aguayo A, Estey E, Kantarjian H, Mansouri T, Gidel C, Keating M, Giles F, Estrov Z, Barlogie B, Albitar M (1999) Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 94(11):3717–3721PubMed

34.

de Bont ES, Neefjes VM, Rosati S, Vellenga E, Kamps WA (2002) New vessel formation and aberrant vegf/vegfr signaling in acute leukemia: Does it matter? Leuk Lymphoma 43(10):1901–1909PubMedCrossRef

35.

Gattei V, Celetti A, Cerrato A, Degan M, De Iuliis A, Rossi FM, Chiappetta G, Consales C, Improta S, Zagonel V, Aldinucci D, Agosti V, Santoro M, Vecchio G, Pinto A, Grieco M (1997) Expression of the ret receptor tyrosine kinase and gdnfr-alpha in normal and leukemic human hematopoietic cells and stromal cells of the bone marrow microenvironment. Blood 89(8):2925–2937PubMed

36.

Gattei V, Degan M, Aldinucci D, De Iuliis A, Rossi FM, Mazzocco FT, Rupolo M, Zagonel V, Pinto A (1998) Differential expression of the ret gene in human acute myeloid leukemia. Ann Hematol 77(5):207–210PubMedCrossRef

37.

Lee JW, Soung YH, Kim SY, Nam SW, Park WS, Lee JY, Yoo NJ, Lee SH (2006) Kinase domain mutation of erbb family genes is uncommon in acute leukemias. Leuk Res 30(2):241–242PubMedCrossRef

38.

Stegmaier K, Corsello SM, Ross KN, Wong JS, Deangelo DJ, Golub TR (2005) Gefitinib induces myeloid differentiation of acute myeloid leukemia. Blood 106(8):2841–2848. doi:10.1182/blood-2005-02-0488 PubMedCrossRef

39.

Nishioka C, Ikezoe T, Takeshita A, Yang J, Tasaka T, Yang Y, Kuwayama Y, Komatsu N, Togitani K, Koeffler HP, Taguchi H (2007) Zd6474 induces growth arrest and apoptosis of human leukemia cells, which is enhanced by concomitant use of a novel mek inhibitor, azd6244. Leukemia 21(6):1308–1310PubMedCrossRef

40.

Berenbaum MC (1981) Criteria for analyzing interactions between biologically active agents. Adv Cancer Res 35:269–335PubMedCrossRef

41.

Gustafson DL, Bradshaw-Pierce EL, Merz AL, Zirrolli JA (2006) Tissue distribution and metabolism of the tyrosine kinase inhibitor zd6474 (zactima) in tumor-bearing nude mice following oral dosing. J Pharmacol Exp Ther 318(2):872–880PubMedCrossRef

42.

Matsuo Y, MacLeod RA, Uphoff CC, Drexler HG, Nishizaki C, Katayama Y, Kimura G, Fujii N, Omoto E, Harada M, Orita K (1997) Two acute monocytic leukemia (aml-m5a) cell lines (molm-13 and molm-14) with interclonal phenotypic heterogeneity showing mll-af9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23). Leukemia 11(9):1469–1477PubMedCrossRef

43.

Lange B, Valtieri M, Santoli D, Caracciolo D, Mavilio F, Gemperlein I, Griffin C, Emanuel B, Finan J, Nowell P et al (1987) Growth factor requirements of childhood acute leukemia: establishment of gm-csf-dependent cell lines. Blood 70(1):192–199PubMed

44.

Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A (1998) The importance of diagnostic cytogenetics on outcome in aml: Analysis of 1, 612 patients entered into the mrc aml 10 trial. The medical research council adult and children’s leukaemia working parties. Blood 92(7):2322–2333PubMed

45.

Balgobind BV, Raimondi SC, Harbott J, Zimmermann M, Alonzo TA, Auvrignon A, Beverloo HB, Chang M, Creutzig U, Dworzak MN, Forestier E, Gibson B, Hasle H, Harrison CJ, Heerema NA, Kaspers GJ, Leszl A, Litvinko N, Nigro LL, Morimoto A, Perot C, Pieters R, Reinhardt D, Rubnitz JE, Smith FO, Stary J, Stasevich I, Strehl S, Taga T, Tomizawa D, Webb D, Zemanova Z, Zwaan CM, van den Heuvel-Eibrink MM (2009) Novel prognostic subgroups in childhood 11q23/mll-rearranged acute myeloid leukemia: results of an international retrospective study. Blood 114(12):2489–2496. doi:10.1182/blood-2009-04-215152 PubMedCrossRef

46.

Armstrong SA, Staunton JE, Silverman LB, Pieters R, den Boer ML, Minden MD, Sallan SE, Lander ES, Golub TR, Korsmeyer SJ (2002) Mll translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 30(1):41–47. doi:10.1038/ng765 PubMedCrossRef

47.

Armstrong SA, Mabon ME, Silverman LB, Li A, Gribben JG, Fox EA, Sallan SE, Korsmeyer SJ (2004) Flt3 mutations in childhood acute lymphoblastic leukemia. Blood 103(9):3544–3546. doi:10.1182/blood-2003-07-2441 PubMedCrossRef

48.

Stubbs MC, Kim YM, Krivtsov AV, Wright RD, Feng Z, Agarwal J, Kung AL, Armstrong SA (2008) Mll-af9 and flt3 cooperation in acute myelogenous leukemia: Development of a model for rapid therapeutic assessment. Leukemia 22(1):66–77. doi:10.1038/sj.leu.2404951 PubMedCrossRef

49.

Troiani T, Lockerbie O, Morrow M, Ciardiello F, Eckhardt SG (2006) Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with zd6474 (zactima), an inhibitor of vegfr and egfr tyrosine kinases. Mol Cancer Ther 5(7):1883–1894PubMedCrossRef

50.

Xu JM, Azzariti A, Colucci G, Paradiso A (2003) The effect of gefitinib (iressa, zd1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines. Cancer Chemother Pharmacol 52(6):442–448PubMedCrossRef

51.

Uittenbogaart CH, Nishanian PG, Anisman DJ, Erikson TK, Fahey JL (1986) Leukemia derived growth factors produced by human malignant t-lymphoid cell lines. Cancer Res 46(3):1219–1223PubMed

52.

Bell JJ, Bhandoola A (2008) The earliest thymic progenitors for t cells possess myeloid lineage potential. Nature 452(7188):764–767. doi:10.1038/nature06840 PubMedCrossRef

53.

Kang HK, Park JS, Kim SK, Choi BH, Pham TN, Zhu XW, Cho D, Nam JH, Kim YJ, Rhee JH, Chung IJ, Kim HJ, Lee JJ (2006) Down-regulation of cellular vascular endothelial growth factor levels induces differentiation of leukemic cells to functional leukemic-dendritic cells in acute myeloid leukemia. Leuk Lymphoma 47(10):2224–2233PubMedCrossRef

54.

Zage PE, Zeng L, Palla S, Fang W, Nilsson MB, Heymach JV, Zweidler-McKay PA (2010) A novel therapeutic combination for neuroblastoma: the vascular endothelial growth factor receptor/epidermal growth factor receptor/rearranged during transfection inhibitor vandetanib with 13-cis-retinoic acid. Cancer. doi:10.1002/cncr.25017

55.

Flaig TW, Su LJ, McCoach C, Li Y, Raben D, Varella-Garcia M, Bemis LT (2009) Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner. BJU Int 103(12):1729–1737. doi:10.1111/j.1464-410X.2009.08367.x PubMedCrossRef

56.

Troiani T, Serkova NJ, Gustafson DL, Henthorn TK, Lockerbie O, Merz A, Long M, Morrow M, Ciardiello F, Eckhardt SG (2007) Investigation of two dosing schedules of vandetanib (zd6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model. Clin Cancer Res 13(21):6450–6458. doi:10.1158/1078-0432.CCR-07-1094 PubMedCrossRef

57.

Dias S, Choy M, Alitalo K, Rafii S (2002) Vascular endothelial growth factor (vegf)-c signaling through flt-4 (vegfr-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood 99(6):2179–2184PubMedCrossRef

58.

Dias S, Hattori K, Zhu Z, Heissig B, Choy M, Lane W, Wu Y, Chadburn A, Hyjek E, Gill M, Hicklin DJ, Witte L, Moore MA, Rafii S (2000) Autocrine stimulation of vegfr-2 activates human leukemic cell growth and migration. J Clin Invest 106(4):511–521PubMedCrossRef

59.

Fragoso R, Pereira T, Wu Y, Zhu Z, Cabecadas J, Dias S (2006) Vegfr-1 (flt-1) activation modulates acute lymphoblastic leukemia localization and survival within the bone marrow, determining the onset of extramedullary disease. Blood 107(4):1608–1616PubMedCrossRef

60.

Hussong JW, Rodgers GM, Shami PJ (2000) Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 95(1):309–313PubMed

61.

Shen HL, Xu W, Wu ZY, Zhou LL, Qin RJ, Tang HR (2007) Vector-based rnai approach to isoform-specific downregulation of vascular endothelial growth factor (vegf)165 expression in human leukemia cells. Leuk Res 31(4):515–521PubMedCrossRef

62.

Mi Y, Lou L (2007) Zd6474 reverses multidrug resistance by directly inhibiting the function of p-glycoprotein. Br J Cancer 97(7):934–940. doi:10.1038/sj.bjc.6603985 PubMedCrossRef

63.

Zheng LS, Wang F, Li YH, Zhang X, Chen LM, Liang YJ, Dai CL, Yan YY, Tao LY, Mi YJ, Yang AK, To KK, Fu LW (2009) Vandetanib (zactima, zd6474) antagonizes abcc1- and abcg2-mediated multidrug resistance by inhibition of their transport function. PLoS One 4(4):e5172. doi:10.1371/journal.pone.0005172 PubMedCrossRef

64.

Treichel RS, Bunuan M, Hahn N, Wee K (2004) Altered conjugate formation and altered apoptosis of multidrug-resistant human leukemia cell line affects susceptibility to killing by activated natural killer (nk) cells. Int J Cancer 108(1):78–85. doi:10.1002/ijc.11555 PubMedCrossRef

65.

Morelli MP, Cascone T, Troiani T, De Vita F, Orditura M, Laus G, Eckhardt SG, Pepe S, Tortora G, Ciardiello F (2005) Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. Ann Oncol 16(Suppl 4):iv61–iv68. doi:10.1093/annonc/mdi910 PubMedCrossRef

Title: Vandetanib mediates anti-leukemia activity by multiple mechanisms and interacts synergistically with DNA damaging agents
Authors: Margaret E. Macy
Deborah DeRyckere
Lia Gore
Publication date: 01-04-2012
Publisher: Springer US
Published in: Investigational New Drugs / Issue 2/2012
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-010-9572-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 2/2012

Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer

In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines

Sensitivity of BRCA2 mutated human cell lines to Aurora kinase inhibition

Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients

Perirenal hematoma associated with bevacizumab treatment

Effect of hepatic or renal impairment on the pharmacokinetics of casopitant, a NK-1 receptor antagonist

Keynote webinar | Spotlight on antibody–drug conjugates in cancer